Plain-English translation of NCT06155318 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a specialized imaging scan called 68Ga-DOTATOC PET/MRI to help doctors better identify and evaluate neuroendocrine tumors—rare cancers that start in hormone-producing cells of the digestive system. The scan combines two types of imaging (PET and MRI) into one session to give doctors more detailed information about your tumor. This combination may help doctors understand your disease better and predict how it might progress.
Most neuroendocrine tumors have specific markers on their surface that this medication can detect. By combining this specialized PET scan with MRI imaging, doctors hope to get a clearer, more complete picture of the tumor with less radiation exposure than traditional imaging alone—especially important for patients who need multiple scans over time.
You likely qualify if…
You likely don't qualify if…
You will come in for a single imaging session where you receive the specialized PET tracer and then undergo a combined PET/MRI scan. The scan allows doctors to see both how your tumor functions (through PET) and its detailed structure (through MRI) in one appointment. The study is being conducted at a research hospital in Italy and will help doctors better understand how to diagnose and monitor patients with your type of tumor.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
Italy
Enrollment target
~300 participants
Started
September 2019
Primary completion
May 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Arturo Chiti
IRCCS San Raffaele
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.